10x Genomics (NYSE:TXG) Releases Quarterly Earnings Results, Misses Expectations By $0.20 EPS

10x Genomics (NYSE:TXG) posted its quarterly earnings results on Thursday. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.20), Fidelity Earnings reports. The firm had revenue of $61.21 million for the quarter, compared to the consensus estimate of $54.33 million.

10x Genomics stock opened at $55.72 on Friday. The business’s 50 day moving average price is $53.55. 10x Genomics has a 1-year low of $45.11 and a 1-year high of $63.38.

In other news, major shareholder Foresite Capital Fund I, L.P. bought 187,500 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were acquired at an average price of $39.00 per share, with a total value of $7,312,500.00. Also, Director Bryan E. Roberts bought 30,000 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were purchased at an average cost of $23.31 per share, for a total transaction of $699,300.00. Insiders have purchased a total of 517,500 shares of company stock worth $19,711,800 in the last ninety days.

Several analysts have recently issued reports on TXG shares. Evercore ISI started coverage on shares of 10x Genomics in a research report on Tuesday, September 24th. They issued an “outperform” rating and a $70.00 price target on the stock. JPMorgan Chase & Co. began coverage on shares of 10x Genomics in a report on Monday, October 7th. They set an “overweight” rating and a $55.00 target price on the stock. Bank of America began coverage on shares of 10x Genomics in a report on Monday, October 7th. They set a “buy” rating and a $62.00 target price on the stock. Finally, Cowen began coverage on shares of 10x Genomics in a report on Monday, October 7th. They set an “outperform” rating and a $55.00 target price on the stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems. It offers chromium instruments, enzymes, reagents, microfluidic chips, and other consumable products, as well as software for analyzing biological systems.

Recommended Story: Diversification For Individual Investors

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.